HUP0001522A2 - Benzimidazol- és imidazo[4,5-c]piridin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
Benzimidazol- és imidazo[4,5-c]piridin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0001522A2 HUP0001522A2 HU0001522A HUP0001522A HUP0001522A2 HU P0001522 A2 HUP0001522 A2 HU P0001522A2 HU 0001522 A HU0001522 A HU 0001522A HU P0001522 A HUP0001522 A HU P0001522A HU P0001522 A2 HUP0001522 A2 HU P0001522A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- general formula
- independently
- hydrogen atom
- nitrogen atoms
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 208000027866 inflammatory disease Diseases 0.000 abstract 3
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 125000003943 azolyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- -1 oxazolidinyl- Chemical group 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A találmány a hízósejtek közvetítette gyulladásosbetegségek megelőzésére és kezelésére szolgáló új vegyületekkel,készítményekkel és módszerekkel foglalkozik. Előnyösek a (II)általános képletű vegyületek, ahol szaggatott vonal jelentéseegymástól függetlenül, adott esetben meglévő kötés; R2 jelentéseegymástól függetlenül alkil-, alkil-oxi-, hidroxilcsoport vagyhalogénatom; R3 jelentése egymástól függetlenül alkil-, alkil-oxi-,hidroxilcsoport vagy halogénatom; X3 jelentése -C(O)- képletű vagy -CR7R8 általános képletű csoport; X8 jelentése -CH(R1)n1,- vagy -C(R1)n1= általános képletű csoport, melyen belül R1 jelentése amino-(1-4 nitrogénatomos) oxazolidinil-, amino-(1-4 nitrogénatomos)azolil-,1-4 nitrogénatomos azolidinil-, 1-4 nitrogénatomos azolil-, -NHC(NH)NR9R9, -C(NR9)R9, -C(NH)NHR10, -C(NH)NR10R10 vagy -(CR11R11)yNH2 általános képletű csoport, vagy X8 további jelentése -N=képletű vagy -NHR(R1)n1- általános képletű csoport, melyen belül R1jelentése -C(NR9)R9, -C(NH)NHR10 vagy -C(NH)NR10R10 általános képletűcsoport, melyen belül R9 jelentése egymástól függetlenül hidrogénatomvagy alkilcsoport és R10 jelentése alkilcsoport; és X9 jelentése -CH(R4)-. vagy, -C(R4)= általános képletű csoport, melyen belül R4jelentése -R12, -OR12, -N(R13)R12, -SR12, -S(O)R12, -S(O)2R12, -S(O)2OR12, -S(O)2N(R13)R12, -N(R13)S(O)2R12, -C(O)R12, -C(O)OR12, -C(O)N(R13)R12, -N(R13)C(O)R12, -OC(O)N(R13)R12, -N(R13)C(O)OR12, -(CH2)n4N(R13)C(O)N(R13)R12, -OP(O)(OR13)OR12 vagy -C(O)N(R14)CH(COOH)R12 képletű, illetve általános képletű csoport;továbbá X9 jelentése -N= képletű vagy -N(R4) általános képletűcsoport, melyen belül R4 jelentése -C(O)R12, -C(O)OR12, -C(O)N(R13)R12, -OC(O)N(R13)R12 vagy -C(O)N(R14)CH(COOH)R12 általánosképletű csoport, R5 jelentése hidrogénatom vagy alkilcsoport; R6jelentése hidrogénatom vagy alkilcsoport, mely adott esetben egy vagykét szubsztituenssel helyettesített, mely szubsztituens egymástólfüggetlenül lehet alkil-oxi-hidroxil- vagy szulfocsoport; R7 jelentésehidrogénatom vagy metilcsoport; és R8 jelentése hidrogénatom, metil-vagy hidroxilcsoport. A vegyületek alkalmasak a légúti gyulladásosbetegségek, például asztma és allergiás szénanátha, más immun eredetűgyulladásos betegség, például rheumatoid arthritis,kötőhártyagyulladás és gyulladásos bélbetegségek, különfélebőrbetegségek, valamint bizonyos vírusos betegségek megelőzésére éskezelésére. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83367497A | 1997-04-07 | 1997-04-07 | |
| PCT/US1997/021849 WO1998045275A1 (en) | 1997-04-07 | 1997-12-01 | Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0001522A2 true HUP0001522A2 (hu) | 2001-05-28 |
| HUP0001522A3 HUP0001522A3 (en) | 2001-08-28 |
Family
ID=25264996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001522A HUP0001522A3 (en) | 1997-04-07 | 1997-12-01 | Benzoimidazole derivatives, process for producing them and pharmaceutical compositions containing them |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1019382A1 (hu) |
| JP (1) | JP2001519806A (hu) |
| KR (1) | KR20010006119A (hu) |
| CN (1) | CN1251579A (hu) |
| AU (1) | AU752064B2 (hu) |
| CA (1) | CA2285454A1 (hu) |
| EE (1) | EE04055B1 (hu) |
| HU (1) | HUP0001522A3 (hu) |
| LT (1) | LT4704B (hu) |
| LV (1) | LV12495B (hu) |
| NO (1) | NO314183B1 (hu) |
| NZ (1) | NZ500029A (hu) |
| PL (1) | PL336233A1 (hu) |
| SI (1) | SI20115A (hu) |
| SK (1) | SK136799A3 (hu) |
| WO (1) | WO1998045275A1 (hu) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| WO1999026932A1 (en) * | 1997-11-26 | 1999-06-03 | Axys Pharmaceuticals, Inc. | By amidino group substituted heterocyclic derivatives and their use as anticoagulants |
| AU1608399A (en) * | 1997-11-26 | 1999-06-15 | Axys Pharmaceuticals, Inc. | Substituted amidinoaryl derivatives and their use as anticoagulants |
| GT199900167A (es) * | 1998-10-01 | 2001-03-21 | Nuevos bis-benzimidazoles. | |
| WO2000020400A1 (en) * | 1998-10-05 | 2000-04-13 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
| EP1189889B1 (en) * | 1999-06-04 | 2003-12-17 | Elan Pharma International Limited | Compositions and methods for inhibiting cell death |
| DE19953899A1 (de) * | 1999-11-10 | 2001-05-17 | Boehringer Ingelheim Pharma | Carboxamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2001052883A1 (en) * | 2000-01-20 | 2001-07-26 | Amgen Inc. | Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| DE10048715A1 (de) * | 2000-09-30 | 2004-05-19 | Grünenthal GmbH | Verwendung von Aminosäure zur Behandlung von Schmerz |
| JP4176477B2 (ja) * | 2001-03-01 | 2008-11-05 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環誘導体 |
| GB0406282D0 (en) * | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| EP2536285B1 (en) | 2010-02-18 | 2018-04-25 | vTv Therapeutics LLC | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| DE102011111991A1 (de) | 2011-08-30 | 2013-02-28 | Lead Discovery Center Gmbh | Neue Cyclosporin-Derivate |
| JP6134731B2 (ja) * | 2011-11-29 | 2017-05-24 | ペロスフィア インコーポレイテッド | 抗凝固剤拮抗剤 |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| CN113727984B (zh) * | 2019-05-21 | 2024-03-15 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3105837A (en) * | 1961-10-20 | 1963-10-01 | Upjohn Co | 2, 2'-alkylenebisbenzimidazoles |
| US3210370A (en) * | 1964-06-22 | 1965-10-05 | Upjohn Co | Process for preparing 2, 2'-methylene-bisareneimiazoles |
| AU7661594A (en) * | 1993-09-22 | 1995-04-10 | Glaxo Wellcome House | Bis(amidinobenzimidazolyl)alkanes as antiviral agents |
| US6815461B1 (en) * | 1994-01-20 | 2004-11-09 | The University Of North Carolina At Chapel Hill | Method of inhibiting retroviral integrase |
| US5693515A (en) * | 1995-04-28 | 1997-12-02 | Arris Pharmaceutical Corporation | Metal complexed serine protease inhibitors |
-
1997
- 1997-12-01 CN CN97182098A patent/CN1251579A/zh active Pending
- 1997-12-01 HU HU0001522A patent/HUP0001522A3/hu unknown
- 1997-12-01 AU AU58950/98A patent/AU752064B2/en not_active Ceased
- 1997-12-01 EE EEP199900477A patent/EE04055B1/xx not_active IP Right Cessation
- 1997-12-01 NZ NZ500029A patent/NZ500029A/en unknown
- 1997-12-01 EP EP97954520A patent/EP1019382A1/en not_active Withdrawn
- 1997-12-01 KR KR1019997009197A patent/KR20010006119A/ko not_active Application Discontinuation
- 1997-12-01 SI SI9720094A patent/SI20115A/sl unknown
- 1997-12-01 WO PCT/US1997/021849 patent/WO1998045275A1/en not_active Application Discontinuation
- 1997-12-01 JP JP54273998A patent/JP2001519806A/ja active Pending
- 1997-12-01 PL PL97336233A patent/PL336233A1/xx unknown
- 1997-12-01 SK SK1367-99A patent/SK136799A3/sk unknown
- 1997-12-01 CA CA002285454A patent/CA2285454A1/en not_active Abandoned
-
1999
- 1999-10-06 NO NO19994858A patent/NO314183B1/no unknown
- 1999-11-02 LV LVP-99-153A patent/LV12495B/en unknown
- 1999-11-05 LT LT99-131A patent/LT4704B/lt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998045275A1 (en) | 1998-10-15 |
| PL336233A1 (en) | 2000-06-19 |
| NO994858D0 (no) | 1999-10-06 |
| NO314183B1 (no) | 2003-02-10 |
| EE9900477A (et) | 2000-06-15 |
| NZ500029A (en) | 2001-02-23 |
| EP1019382A1 (en) | 2000-07-19 |
| SI20115A (sl) | 2000-06-30 |
| AU752064B2 (en) | 2002-09-05 |
| LT4704B (lt) | 2000-09-25 |
| CN1251579A (zh) | 2000-04-26 |
| KR20010006119A (ko) | 2001-01-26 |
| AU5895098A (en) | 1998-10-30 |
| HUP0001522A3 (en) | 2001-08-28 |
| LV12495B (en) | 2001-01-20 |
| EE04055B1 (et) | 2003-06-16 |
| LT99131A (en) | 2000-04-25 |
| LV12495A (en) | 2000-06-20 |
| JP2001519806A (ja) | 2001-10-23 |
| NO994858L (no) | 1999-12-06 |
| CA2285454A1 (en) | 1998-10-15 |
| SK136799A3 (en) | 2000-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0001522A2 (hu) | Benzimidazol- és imidazo[4,5-c]piridin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0402065A2 (hu) | Heterobiciklikus szerkezetû hepatitis C vírus polimeráz inhibitorok, eljárás az elõállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| ATE323678T1 (de) | Tri-aryl-säurederivate als ppar rezeptor liganden | |
| NO923618L (no) | Benzanilid-derivater | |
| NO20051411L (no) | Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav | |
| PT92153B (pt) | Processo para a preparacao de derivados de 1,4-diazepina e de composicoes farmaceuticas que os contem | |
| HUP9802300A2 (hu) | N-heteroaril-piridin-szulfonamid származékok, ezeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk | |
| ATE113281T1 (de) | Pyrazol-derivate, verfahren zu deren herstellung und anwendung. | |
| ATE206122T1 (de) | Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind | |
| JPS63225374A (ja) | チアゾ−ル誘導体、その製造法およびその組成物 | |
| HUP0203245A2 (hu) | Foszfodiészteráz VII-inhibitorként használható imidazopiridinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| FR2400504A1 (fr) | Leuco-anthraquinones et leurs formes tautomeres, leurs procedes de preparation et leur utilisation pour lutter contre les maladies cancereuses | |
| NO158578C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater. | |
| ES2077173T3 (es) | Composiciones y compuestos de eter vinilaromatico y procedimiento para su fabricacion. | |
| DK0595111T4 (da) | Carbazolonderivater og fremgangsmåde til deres fremstilling | |
| NO176176B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive arylsulfonamider | |
| HUP0401831A2 (hu) | Szubsztituált 1H-kinolin-2-on-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP9801056A2 (hu) | Apolipoprotein-B szintézist gátló triazolonszármazékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| JP3754467B2 (ja) | 新規なナフチリドンまたはキノロン化合物もしくはそれらの塩、それらからなる抗ウイルス剤 | |
| DE59010865D1 (de) | N-substituierte naphthalimide, ihre herstellung und verwendung | |
| DK1250335T3 (da) | Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner | |
| AR045154A1 (es) | Compuestos piperidinicos 1,4-disustituidos, su preparacion, composiciones que los contienen, y su uso | |
| CA2192596A1 (en) | 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety | |
| ES511642A0 (es) | "metodo de preparar sulfohalogenuros". | |
| HUP9901030A2 (hu) | Helyettesített N-metil-N-(4-(4-(1H-benzimidazol-2-il)-amino)-piperidin-1-il)-2-(aril)-butil)-benzamid-származékok, a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk |